NeoVisc ONE (hyaluronic acid) / Miravo - LARVOL DELTA

Miravo Healthcare Announces First Quarter 2022 Results (Businesswire) - "Nuvo Pharmaceuticals Inc...d/b/a Miravo Healthcare (Miravo or the Company)...today announced its financial and operational results for the three months ended March 31, 2022....Revenue attributable to the Commercial Business segment increased during the three months ended March 31, 2022 due to a $2.2 million increase in sales of the Company’s promoted products (Blexten, Cambia, Suvexx and NeoVisc®) and a $0.2 million increase in sales of the Company’s mature products....The Production and Service Business segment revenue decreased during the three months ended March 31, 2022, primarily due to a decrease in Pennsaid 2% product sales, slightly offset by an increase in sales of Pennsaid and Resultz."

Commercial • CNS Disorders • Osteoarthritis • Pain

Miravo Healthcare Announces the Canadian Commercial Launch of NeoVisc+ and NeoVisc ONE for the Treatment of Pain and Improvement of Joint Functionality of the Knee (Canada Newswire) - "Nuvo Pharmaceuticals...today announced the commercial launch of NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada...The launch of NeoVisc+ and NeoVisc ONE provides doctors and patients with innovative options for the treatment of knee pain."

Launch Canada • Osteoarthritis • Pain